Literature DB >> 26149884

Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology.

Khê Hoang-Xuan1, Eric Bessell2, Jacoline Bromberg3, Andreas F Hottinger4, Matthias Preusser5, Roberta Rudà6, Uwe Schlegel7, Tali Siegal8, Carole Soussain9, Ufuk Abacioglu10, Nathalie Cassoux11, Martina Deckert12, Clemens M F Dirven13, Andrés J M Ferreri14, Francesc Graus15, Roger Henriksson16, Ulrich Herrlinger17, Martin Taphoorn18, Riccardo Soffietti6, Michael Weller19.   

Abstract

The management of primary CNS lymphoma is one of the most controversial topics in neuro-oncology because of the complexity of the disease and the very few controlled studies available. In 2013, the European Association of Neuro-Oncology created a multidisciplinary task force to establish evidence-based guidelines for immunocompetent adults with primary CNS lymphoma. In this Review, we present these guidelines, which provide consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, we address aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients. The guidelines should aid clinicians in their daily practice and decision making, and serve as a basis for future investigations in neuro-oncology.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26149884     DOI: 10.1016/S1470-2045(15)00076-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  126 in total

1.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

2.  Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry.

Authors:  Heiner Zimmermann; Mirko Nitsche; Christiane Pott; Petra Reinke; Nina Babel; Robert M Hermann; Ingeborg A Hauser; Dennis Hahn; Matthias Ritgen; Claudia Pietschmann; Wolfram Klapper; Ioannis Anagnostopoulos; Ralf U Trappe
Journal:  Ann Hematol       Date:  2021-05-11       Impact factor: 3.673

3.  The challenge of adequate imaging surveillance in primary central nervous system lymphoma.

Authors:  Uwe Schlegel; Agnieszka Korfel
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

4.  Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015.

Authors:  M van der Meulen; A G Dinmohamed; O Visser; J K Doorduijn; J E C Bromberg
Journal:  Leukemia       Date:  2017-04-28       Impact factor: 11.528

5.  Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI.

Authors:  Fu-Hua Lin; Xiang-Heng Zhang; Ji Zhang; Zhen-Qiang He; Hao Duan; Chao Ke; Ke Sai; Xiao-Bing Jiang; Fuad Al-Nahari; Shao-Yan Xi; Yong-Gao Mou
Journal:  J Neurooncol       Date:  2018-08-16       Impact factor: 4.130

Review 6.  Intraocular lymphoma.

Authors:  Li-Juan Tang; Chang-Lin Gu; Ping Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

7.  Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.

Authors:  Sophie Langner-Lemercier; Caroline Houillier; Carole Soussain; Hervé Ghesquières; Olivier Chinot; Luc Taillandier; Pierre Soubeyran; Thierry Lamy; Franck Morschhauser; Alexandra Benouaich-Amiel; Guido Ahle; Marie-Pierre Moles-Moreau; Cécile Moluçon-Chabrot; Pascal Bourquard; Ghandi Damaj; Fabrice Jardin; Delphine Larrieu; Emmanuel Gyan; Remy Gressin; Arnaud Jaccard; Sylvain Choquet; Annie Brion; Olivier Casasnovas; Philippe Colin; Oumedaly Reman; Adrian Tempescul; Jean-Pierre Marolleau; Michel Fabbro; Florian Naudet; Khê Hoang-Xuan; Roch Houot
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

8.  Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome.

Authors:  Monique C Minnema; Eva Kimby; Shirley D'Sa; Luc-Matthieu Fornecker; Stéphanie Poulain; Tom J Snijders; Efstathios Kastritis; Stéphane Kremer; Aikaterini Fitsiori; Laurence Simon; Frédéric Davi; Michael Lunn; Jorge J Castillo; Christopher J Patterson; Magali Le Garff-Tavernier; Myrto Costopoulos; Véronique Leblond; Marie-José Kersten; Meletios A Dimopoulos; Steven P Treon
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

9.  Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).

Authors:  Hanne Kuitunen; Susanna Tokola; Topi Siniluoto; Matti Isokangas; Eila Sonkajärvi; Seppo Alahuhta; Taina Turpeenniemi-Hujanen; Esa Jantunen; Tapio Nousiainen; Kaija Vasala; Outi Kuittinen
Journal:  J Neurooncol       Date:  2016-10-17       Impact factor: 4.130

10.  Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.

Authors:  Caroline Houillier; Hervé Ghesquières; Cécile Chabrot; Carole Soussain; Guido Ahle; Sylvain Choquet; Emmanuelle Nicolas-Virelizier; Jacques-Olivier Bay; Jacques Vargaftig; Claude Gaultier; Valérie Touitou; Nadine Martin-Duverneuil; Nathalie Cassoux; Magali Le Garff-Tavernier; Myrto Costopoulos; Pierre Faurie; Khê Hoang-Xuan
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.